Ipamorelin

Ipamorelin is a synthetic pentapeptide and selective agonist of the ghrelin receptor (GHS-R1a). Published preclinical studies have examined its receptor binding selectivity and interaction with pituitary signaling constructs in vitro. Pepticore supplies this compound exclusively as a laboratory reference material. No biological outcomes or suitability for human use is implied or established.

Ipamorelin was developed in the 1990s during research into growth hormone secretagogue receptor binding. Unlike earlier structural analogs such as GHRP-6, Ipamorelin demonstrated a distinct receptor selectivity profile in preclinical assay models. It has since been examined in studies investigating pituitary receptor signaling and GH-dependent pathway interactions in laboratory settings.

Peer-reviewed literature has examined Ipamorelin's binding characteristics across the following in vitro assay categories:

• Endocrine receptor assays: GHS-R1a binding and selectivity profiling
• Pituitary signaling studies: GH secretagogue receptor interaction modeling
• IGF-1 pathway assays: downstream receptor interaction studies
• Metabolic cell culture models: receptor pathway mapping

All findings referenced here are sourced from third-party peer-reviewed publications. Pepticore makes no independent claims regarding biological activity, efficacy, or outcomes for this compound.

Published literature examining Ipamorelin's receptor binding properties is accessible via PubMed (CAS: 170851-70-4).